Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease
Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease
复制标题
DOI：
10.1111/eci.12192
复制
发表时间：
2014-01-01
影响因子：
5.5
通讯作者：
Eugenia Miquilena-Colina, Maria
中科院分区：
文献类型：
--
作者：
Garcia-Monzon, Carmelo;Lo Iacono, Oreste;Eugenia Miquilena-Colina, Maria
背景可溶性CD36(SCD36)与胰岛素抵抗有关，但尚无证据表明其与肝脏脂肪含量的关系。材料与方法对227例非酒精性脂肪性肝病、87例慢性丙型肝炎和85例肝组织学正常的患者进行研究。根据Kleiner的组织学评分系统对脂肪变性进行分级。结果单纯脂肪肝患者血清sCD36水平显著高于非酒精性脂肪肝患者(361.4+/-286.4 pg/mLvs.173.9+/-137.4 pg/m L；P
Background Soluble CD36 (sCD36) clusters with insulin resistance, but no evidence exists on its relationship with hepatic fat content. We determined sCD36 to assess its link to steatosis in nonalcoholic fatty liver disease (NAFLD) and chronic hepatitis C (CHC) patients.Materials and methods Two hundred and twenty-seven NAFLD, eighty-seven CHC, and eighty-five patients with histologically normal liver (NL) were studied. Steatosis was graded by Kleiner's histological scoring system. Serum sCD36 and hepatic CD36 expression was assessed by immunoassay and immunohistochemistry, respectively.Results In NAFLD, serum sCD36 levels were significantly higher in simple steatosis than in NL (361.4 +/- 286.4 vs. 173.9 +/- 137.4 pg/mL, respectively; P